| Objective:1. To detect the expression of Claudin-1and ZO-1in benign breast disease and breast cancer tissues respectively.2. To assess their relationships with oncogenesis, invasion and metastasis of breast cancer.Methods:Immunohistochemical SP method was used to detect the expression of Claudin-1and ZO-1in34benign breast disease tissues and104breast cancer tissues with different clinical stages and pathological characters.Results:1. The positive rate of Claudin-1expression in benign breast disease tissues and breast cancer tissues was73.5%(25/34) and30.8%(33/104) respectively. Claudin-1expression in breast cancer tissues was significantly lower than that in benign breast disease tissues (P<0.05).2. The expression of Claudin-1protein in breast cancer tissues was significantly associated with clinical stages and lymphatic metastasis (P<0.05), but not significantly correlated with the tumor size or Her-2phenotype (P>0.05).3. The positive rate of ZO-1expression in benign breast disease tissues and breast cancer tissues was79.4%(27/34) and32.7%(34/104) respectively. ZO-1expression in breast cancer tissues was significantly lower than that in benign breast disease tissues (P<0.05).4. The expression of ZO-1protein in breast cancer was significantly associated with clinical stage, lymphatic metastasis and Her-2phenotype (P<0.05), but not significantly correlated with the tumor size (P>0.05).Conclusions:1. The reduced or absent expression of Claudin-1or ZO-1has a relationship with the oncogenesis and development of breast cancer.2. The cytoplasmic translocation of ZO-1may be correlated with the expression of Her-2in breast cancer. |
PDF Full Text Request